OJJAARA (momelotinib) tablets, for oral use Initial U.S. Approval: 2023
OJJAARA is used to treat a certain type of cancer (myelofibrosis) in people with anemia (low red blood cell count). Momelotinib belongs to a class of drugs known as kinase inhibitors. It works by blocking your body from producing substances called growth factors.
| Brand Name: | OJJAARA |
| Generic Name: | momelotinib |
| Strength: | • Tablets: 100 mg, 150 mg, 200 mg. |
| Manufacturer: | GlaxoSmithKline |
| Approved By: | EMA, USFDA |
Source Details: Patient Information
IPN, New Delhi can facilitate patient to import of “OJJAARA (momelotinib) tablets” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for OJJAARA (momelotinib) tablets price list or cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.
Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.